Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMERICAN HOME PRODUCTS LICENSES INTO AIDS DRUG DEVELOPMENT

Executive Summary

AMERICAN HOME PRODUCTS LICENSES INTO AIDS DRUG DEVELOPMENT: First AHP product in clinicals will be AS-101. AHP announced March 16 that it has acquired exclusive worldwide rights to AS-101 via a license with a joint venture of National Patent Development Corp. and Bar-Ilan University of Israel. AHP is assuming responsibility for development and marketing of the compound. AHP noted that an IND has been approved for study of the drug in AIDS patients. Clinical trials with AS-101 are expected to begin at an undisclosed "major medical center" in New York City within a month to six weeks. AHP says that human studies in France, Israel, and Mexico are ongoing in AIDS and "certain forms of cancer." The National Institute of Allergy & Infectious Diseases is also interest in AS-101. NIAID said it is "actively considering studying" the immunomodulator. The final protocol for a Phase I dose ranging study in AIDS patients has been approved and an IND is "in the process" of being filed, NIAID said. Under the terms of the agreement, AHP explained, the joint venture company, NPDC-AS101, will manufacture "the principal ingredient of the drug and American Home Products will make upfront payments, additional progress payments and pay a royalty on net sales."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS013358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel